A Phase 2 Study of Sitravatinib in Combination With Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma
What is the purpose of this trial?
The study will evaluate the clinical activity of nivolumab in combination with the investigational agent sitravatinib in patients with advanced or metastatic urothelial carcinoma.
- Ages18 years and older
- Trial withMirati Therapeutics
- Start Date02/23/2020
- End Date01/30/2022
- Last Updated04/15/2021
- Study HIC#2000024557